Related Experiment Video
Updated: May 25, 2026
14:10
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Albumin nanoparticles with predictable size by desolvation procedure
B von Storp1, A Engel, A Boeker
1Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, Corrensstr. 1 , D-48149 Muenster, Germany.
Journal of Microencapsulation
|February 15, 2012
Summary
Human serum albumin (HSA) nanoparticles are effective drug carriers. Optimizing desolvation agents and process parameters, like stirring rates, allows control over nanoparticle size and characteristics for improved drug delivery formulations.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Pharmaceutical Sciences
Background:
- Human serum albumin (HSA) nanoparticles are recognized as viable carriers for drug delivery applications.
- The desolvation method is frequently employed for producing protein-based nanoparticles, but process parameters significantly impact formulation characteristics such as size, size distribution, and yield.
- Understanding these parameter effects is critical for reproducible and effective nanoparticle preparation.
Purpose of the Study:
- To investigate the impact of various desolvating agents on the characteristics and cytotoxicity of human serum albumin (HSA) nanoparticles.
- To evaluate the influence of stirring rates, pre-stirring of HSA solutions, and the continuous addition of desolvating agent on nanoparticle formation.
Main Methods:
- Preparation of HSA nanoparticles using a desolvation technique.
- Systematic variation of desolvating agents (e.g., methanol, ethanol) and process parameters (stirring rates, addition methods).
- Characterization of nanoparticle size, size distribution, morphology, and assessment of cytotoxicity in cell culture models.
Main Results:
- Particle size can be predicted based on the dielectric constant of the desolvation medium.
- A combination of methanol and ethanol as desolvating agents yielded highly spherical HSA nanoparticles in the 50–80 nm size range.
- Different stirring rates and addition methods influenced particle characteristics.
Conclusions:
- The choice of desolvating agent and process parameters significantly affects HSA nanoparticle properties.
- Controlled preparation methods, particularly using specific solvent mixtures like methanol and ethanol, enable the production of small, spherical HSA nanoparticles suitable for drug delivery.
- Further research into process optimization can lead to tailored nanoparticle formulations for targeted therapeutic applications.
